TCR Therapy Drug Pipeline Analysis Report 2025
Description
TCR (T-cell receptor) therapy is emerging as a groundbreaking approach in cancer treatment, addressing the high unmet clinical need for better solid tumor therapies. In comparison to CAR-T therapy, which has shown limited success in solid tumors, TCR therapy leverages the ability to target antigenic peptides derived from protein degradation, granting access to the entire proteome. This makes it a powerful option for patients with solid tumors, which account for 95% of all cancer cases, and for those unresponsive to checkpoint inhibitors. The growing focus on personalized immunotherapy and innovative biotechnological advancements is propelling TCR therapy drug pipeline growth, transforming cancer care.
Report Coverage
The TCR Therapy Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into TCR therapy therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for TCR therapy. The TCR therapy report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The TCR therapy pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with TCR therapy treatment guidelines to ensure optimal care practices.
The assessment portion will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to TCR therapy.
TCR Therapy Drug Pipeline Outlook
TCR therapy is an emerging immunotherapy that modifies a patient’s T-cells to recognize and attack cancer cells. By genetically engineering T-cells to target tumor-specific antigens, this approach enhances the ability of the immune system to fight cancers, particularly those resistant to traditional treatments, such as solid tumors. TCR therapy holds significant potential in addressing unmet needs in oncology, offering a promising solution for patients with hard-to-treat cancers, including those who do not respond to other immunotherapies.
The TCR therapy drug pipeline is growing due to advancements in gene editing enabling precise targeting of cancer antigens. Increased research investments in solid tumor treatments, along with innovations in antigen identification and a focus on personalized immunotherapies, are enhancing TCR therapy efficacy and addressing unmet needs, expanding its clinical potential for solid tumors.
TCR Therapy Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of TCR therapy drug candidates based on several segmentations, including:
By Phase
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase I covers a major share of the total TCR therapy clinical trials.
TCR Therapy – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the TCR therapy pipeline analysis include small molecules, monoclonal antibodies, gene therapies, and others. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for TCR therapy.
TCR Therapy Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR report for the TCR therapy report insights includes the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in TCR Therapy clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for TCR therapy. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of TCR therapy drug candidates.
Biological: E7 TCR-T cells therapy
This Phase II study, sponsored by Rutgers University, evaluates the E7 TCR-T cell immunotherapy combined with Aldesleukin for treating metastatic HPV-associated cancers. Targeting the HPV16 E7 oncoprotein, the trial aims to determine tumor response rates and safety. With 20 participants, the study began in March 2023 and is expected to conclude by January 2025.
Drug: CRTE7A2-01 TCR-T cell therapy
Sponsored by Corregene Biotechnology Co., Ltd., the Phase 1 study is designed to assess the safety, tolerability, and efficacy of CRTE7A2-01 TCR-T cells in treating HPV16-positive advanced cervical, anal, and head and neck cancers. The primary objective is to determine the recommended phase 2 dose (RP2D). The study is expected to conclude by April 2028.
Reasons To Buy This Report
The TCR Therapy Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for TCR therapy. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within TCR therapy pipeline insights.
Key Questions Answered in the TCR Therapy – Pipeline Insight Report
Global Clinical Trials Market
Head and Neck Cancer Drug Pipeline Analysis
Report Coverage
The TCR Therapy Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into TCR therapy therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for TCR therapy. The TCR therapy report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The TCR therapy pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with TCR therapy treatment guidelines to ensure optimal care practices.
The assessment portion will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to TCR therapy.
TCR Therapy Drug Pipeline Outlook
TCR therapy is an emerging immunotherapy that modifies a patient’s T-cells to recognize and attack cancer cells. By genetically engineering T-cells to target tumor-specific antigens, this approach enhances the ability of the immune system to fight cancers, particularly those resistant to traditional treatments, such as solid tumors. TCR therapy holds significant potential in addressing unmet needs in oncology, offering a promising solution for patients with hard-to-treat cancers, including those who do not respond to other immunotherapies.
The TCR therapy drug pipeline is growing due to advancements in gene editing enabling precise targeting of cancer antigens. Increased research investments in solid tumor treatments, along with innovations in antigen identification and a focus on personalized immunotherapies, are enhancing TCR therapy efficacy and addressing unmet needs, expanding its clinical potential for solid tumors.
TCR Therapy Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of TCR therapy drug candidates based on several segmentations, including:
By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
- Small Molecules
- Monoclonal Antibodies
- Gene Therapies
- Others
- Oral
- Parenteral
- Others
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase I covers a major share of the total TCR therapy clinical trials.
TCR Therapy – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the TCR therapy pipeline analysis include small molecules, monoclonal antibodies, gene therapies, and others. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for TCR therapy.
TCR Therapy Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR report for the TCR therapy report insights includes the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in TCR Therapy clinical trials:
- Corregene Biotechnology Co., Ltd
- SCG Cell Therapy Pte. Ltd.
- GlaxoSmithKline
- Cell Medica Ltd.H
- RYZ Biotech Co.
- Alaunos Therapeutics
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for TCR therapy. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of TCR therapy drug candidates.
Biological: E7 TCR-T cells therapy
This Phase II study, sponsored by Rutgers University, evaluates the E7 TCR-T cell immunotherapy combined with Aldesleukin for treating metastatic HPV-associated cancers. Targeting the HPV16 E7 oncoprotein, the trial aims to determine tumor response rates and safety. With 20 participants, the study began in March 2023 and is expected to conclude by January 2025.
Drug: CRTE7A2-01 TCR-T cell therapy
Sponsored by Corregene Biotechnology Co., Ltd., the Phase 1 study is designed to assess the safety, tolerability, and efficacy of CRTE7A2-01 TCR-T cells in treating HPV16-positive advanced cervical, anal, and head and neck cancers. The primary objective is to determine the recommended phase 2 dose (RP2D). The study is expected to conclude by April 2028.
Reasons To Buy This Report
The TCR Therapy Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for TCR therapy. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within TCR therapy pipeline insights.
Key Questions Answered in the TCR Therapy – Pipeline Insight Report
- Which companies/institutions are leading the TCR therapy drug development?
- What is the efficacy and safety profile of TCR therapy pipeline drugs?
- Which company is leading the TCR therapy pipeline development activities?
- What is the current TCR therapy commercial assessment?
- What are the opportunities and challenges present in the TCR therapy drug pipeline landscape?
- What is the efficacy and safety profile of TCR therapy pipeline drugs?
- Which company is conducting major trials for TCR therapy drugs?
- Which companies/institutions are involved in TCR therapy collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in TCR therapy?
Global Clinical Trials Market
Head and Neck Cancer Drug Pipeline Analysis
Table of Contents
200 Pages
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology & Assumptions
- 2 Executive Summary
- 3 Overview of TCR Therapy
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Diagnosis
- 3.5 Treatment
- 4 Patient Profile: TCR Therapy
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 TCR Therapy: Epidemiology Snapshot
- 5.1 TCR Therapy Incidence by Key Markets
- 5.2 TCR Therapy – Patients Seeking Treatment in Key Markets
- 6 TCR Therapy: Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 TCR Therapy: Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 TCR Therapy, Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of TCR Therapy Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 TCR Therapy Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
- 10.1 Comparative Analysis for Late-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 Drug 1
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 Other Drugs
- 11 TCR Therapy Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 Biological: E7 TCR-T Cell Immunotherapy, Drug: Aldesleukin
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 Other Drugs
- 12 TCR Therapy Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
- 12.1 Comparative Analysis for Early-Stage Drugs
- 12.1.1 Study Type
- 12.1.2 Recruitment Status
- 12.1.3 Company
- 12.1.4 Funder Type
- 12.2 Product Level Analysis*
- 12.2.1 Biological: SCG101
- 12.2.1.1 Product Description
- 12.2.1.2 Trial ID
- 12.2.1.3 Sponsor Name
- 12.2.1.4 Study Type
- 12.2.1.5 Drug Class
- 12.2.1.6 Eligibility Criteria
- 12.2.1.7 Study Record Dates
- 12.2.1.7.1 First Submitted
- 12.2.1.7.2 First Posted
- 12.2.1.7.3 Last Update Posted
- 12.2.1.7.4 Last Verified
- 12.2.1.8 Indication
- 12.2.1.9 Study Design
- 12.2.1.10 Recruitment Status
- 12.2.1.11 Enrollment (Estimated)
- 12.2.1.12 Location Countries
- 12.2.2 Drug: CRTE7A2-01 TCR-T cell therapy
- 12.2.3 Biological: KK-LC-1 TCR-T cells, Drug: Aldesleukin
- 12.2.4 Other Drugs
- 13 TCR Therapy Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
- 13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
- 13.1.1 Study Type
- 13.1.2 Recruitment Status
- 13.1.3 Company
- 13.1.4 Funder Type
- 13.2 Product Level Analysis*
- 13.2.1 Biological: Autologous, Engineered T Cells Targeting TP53 R248Q
- 13.2.1.1 Product Description
- 13.2.1.2 Trial ID
- 13.2.1.3 Sponsor Name
- 13.2.1.4 Study Type
- 13.2.1.5 Drug Class
- 13.2.1.6 Eligibility Criteria
- 13.2.1.7 Study Record Dates
- 13.2.1.7.1 First Submitted
- 13.2.1.7.2 First Posted
- 13.2.1.7.3 Last Update Posted
- 13.2.1.7.4 Last Verified
- 13.2.1.8 Indication
- 13.2.1.9 Study Design
- 13.2.1.10 Recruitment Status
- 13.2.1.11 Enrollment (Estimated)
- 13.2.1.12 Location Countries
- 13.2.2 Other Drugs
- 14 TCR Therapy, Key Drug Pipeline Companies
- 14.1 Corregene Biotechnology Co., Ltd.
- 14.1.1 Company Snapshot
- 14.1.2 Pipeline Product Portfolio
- 14.1.3 Financial Analysis
- 14.1.4 Recent News and Developments
- 14.2 SCG Cell Therapy Pte. Ltd.
- 14.2.1 Company Snapshot
- 14.2.2 Pipeline Product Portfolio
- 14.2.3 Financial Analysis
- 14.2.4 Recent News and Developments
- 14.3 GlaxoSmithKline
- 14.3.1 Company Snapshot
- 14.3.2 Pipeline Product Portfolio
- 14.3.3 Financial Analysis
- 14.3.4 Recent News and Developments
- 14.4 Cell Medica Ltd.
- 14.4.1 Company Snapshot
- 14.4.2 Pipeline Product Portfolio
- 14.4.3 Financial Analysis
- 14.4.4 Recent News and Developments
- 14.5 HRYZ Biotech Co.
- 14.5.1 Company Snapshot
- 14.5.2 Pipeline Product Portfolio
- 14.5.3 Financial Analysis
- 14.5.4 Recent News and Developments
- 14.6 Alaunos Therapeutics
- 14.6.1 Company Snapshot
- 14.6.2 Pipeline Product Portfolio
- 14.6.3 Financial Analysis
- 14.6.4 Recent News and Developments
- 15 Regulatory Framework for Drug Approval, By Region
- 16 Terminated or Suspended Pipeline Products
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
